Conexiant’s news site is now MDSpire News. Learn more
Advertisement
GRAPPA, EULAR Criteria May Identify Complex PsA
Application of newly proposed GRAPPA and EULAR criteria in a longitudinal cohort identified progressively smaller groups of patients with early psoriatic arthritis who experienced persistently worse patient-reported outcomes.
To evaluate the frequency of patients with early psoriatic arthritis meeting the GRAPPA and EULAR criteria for complex-to-manage and difficult-to-manage disease.
Approach:
Study Design: Retrospective analysis of data from the Dutch Southwest Early Psoriatic Arthritis cohort, involving 885 newly diagnosed, disease-modifying antirheumatic drug-naïve patients.
Criteria Application: The 2025 GRAPPA and EULAR definitions for complex-to-manage, treatment-refractory, difficult-to-manage diseases were applied to the cohort.
Follow-Up: Patients were followed for a mean of 40 months to assess outcomes.
Key Findings:
20% of patients met the GRAPPA-C2M definition, while only 4% met the EULAR-D2M and EULAR-TR definitions, and 1% met the GRAPPA-TR definition.
The GRAPPA-C2M criteria identified patients earlier in the disease course compared to EULAR definitions.
Patients meeting any of the definitions reported worse long-term patient-reported outcomes, including greater disability and pain, and were more likely to be female, have a higher body mass index, longer symptom duration, greater skin involvement, and enthesitis at baseline.
Interpretation:
Limitations:
Criteria were applied retrospectively using observational data.
Some criteria were assessed using proxy measures.
Generalizability may be limited as all patients were enrolled at Dutch clinical centers.
Published evidence linked liraglutide and semaglutide to improvements in psoriasis severity, inflammatory markers, and metabolic outcomes, while evidence in psoriatic arthritis remained sparse.
